




FIG. 1




FIG. 2B

FIG. 2A




FIG. 2D




FIG. 2C




FIG. 3




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 7




FIG. 8




FIG. 9A

FIG. 9B




FIG. 9D




FIG. 9C




FIG. 10




FIG. 11




FIG. 12




FIG. 13








FIG. 14

**FIG. 15A**

**FIG. 15B**




FIG. 16A




FIG. 16B




FIG. 17A





FIG. 17B



REP1



MLA (CTL)


FIG. 18A

REP2



MLA (CTL)

FIG. 18B







FIG. 19A

REP2



Ag001-02 (CTL)

FIG. 19B




FIG. 20A




FIG. 20B

+ Dasatinib | 37 | + Irrelevant Mix

Complete Tetramer Stain (PBMC only cells)




FIG. 21A

Dasatinib | RT | Irrelevant Mix




FIG. 21B

α Col6A3 T-Cells




FIG. 22A

α MLA T-Cells




FIG. 22B

**Mix 10:1 stained MLA T-cells
with stained Col6A3 T-cells**




FIG. 22C

α CD45
Col6A3-APC & PE




FIG. 23A

α CD45
Col6A3-PE





FIG. 23B



	2DTet+	1DTet+
R squared	0.9394	0.8756

FIG. 23C

α CD45
Col6A3-APC & PE



Codm-R1-A :: COL6A3-APC-A

FIG. 24A

α CD45
Col6A3-PE



Comp-R1-A :: COL6A3-APC-A

FIG. 24B




FIG. 24C




FIG. 24D




FIG. 25A




FIG. 25B





FIG. 25C

D1



D2





FIG. 25D

E1 α MLA T-Cells
2DTet^{APC+PE} + 1^oAPC+PE



E2 α MLA T-Cells
2DTet^{PE+BV421} + 1^oPE





FIG. 25E









FIG. 27








Condition	Average Irrelevant Tet Negative of 2D Tet Positive
No Irrelevant Mix	99.3% (+/- 1.14)
Yes Irrelevant Mix	3.77% (+/- 2.7)

FIG. 28C

**FIG. 29**




FIG. 30





FIG. 31A







FIG. 32



- Dasatinib + Irrelevant Mix

RT
(SI = 15.9)






FIG. 33B

+ Dasatinib | 37 | + Irrelevant Mix | 15.6 S.I.




Comp-V1-A :: ColTet BV421-A



Comp-R1-A :: Irr Tet Mix APC-A

FIG. 34A







FIG. 34C

- Dasatinib | RT | + Irrelevant Mix | 10.2 S.I.



Comp-R1-A :: Irr Tet Mix APC-A

Comp-V1-A :: ColTet BV421-A

FIG. 35A




FIG. 35B




FIG. 35C





FIG. 36A



Comp-R1-A:lrT Mix Tet APC-A

FIG. 36B





FIG. 36C






FIG. 37B




FIG. 37C





FIG. 38






FIG. 40A




FIG. 40B




FIG. 40C





FIG. 40D






FIG. 41




FIG. 42




FIG. 43




FIG. 44




FIG. 45